Nanobiotix Reports 2024 Financial Results, Extends Cash Runway to Mid-2026

PARIS and CAMBRIDGE, Mass. – Nanobiotix, a late-stage biotechnology company developing nanotherapeutic approaches for cancer treatment, has provided an operational update and reported its full-year 2024 financial results. The company's financial position has been strengthened through a $20 million milestone payment from Johnson & Johnson and the transfer of sponsorship for the NANORAY-312 study.

The company's global development program for JNJ-1900 (NBTXR3) is proceeding as planned, with a focus on head and neck cancers and lung cancer. The NANORAY-312 study in the U.S. has transferred sponsorship to Johnson & Johnson, with a global sponsorship transfer anticipated by the third quarter of 2025. Patient enrollment has also commenced in the CONVERGE study, evaluating JNJ-1900 (NBTXR3) in combination with treatment for unresectable stage 3 non-small cell lung cancer.

Nanobiotix also launched the Curadigm platform, designed for the development of next-generation nanotherapeutics. The company's strategy has focused on bolstering its financial standing and achieving long-term sustainability and growth. As of the end of 2024, the company held €49.7 million in cash and cash equivalents, with its cash runway now extended into mid-2026.

Clinical data readouts are expected in 2025 from several ongoing studies, including those involving head and neck cancer, pancreatic cancer, lung cancer, and melanoma. The company has also filed its universal registration document with the French financial markets authority (AMF) and its annual report on Form 20-F with the U.S. Securities and Exchange Commission (SEC).